Bayer gets Health Canada approval for treatment of GIST with Stivarga

German pharmaceutical firm Bayer has received approval from Health Canada for its Stivarga (regorafenib tablets) to treat adult patients with metastatic and unresectable gastrointestinal stromal tumours (GIST).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news